This is a working overview of CAS Registry Number, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-30 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
== Adrenomedullary hormones == Adrenomedullary hormones are catecholamines secreted from the adrenal medulla by chromaffin cells, neurosecretory cells connected to the central nervous system. The synthesis, storage (in chromaffin cells) and release of catecholamines is co-regulated by synaptic input from their respective pre-synaptic sympathetic neurons, as well as hormonal and local inputs. The adrenomedullary hormones are:
One condition that can affect the pharmacological properties of drugs is protein degradation caused by spaceflight, predicted to be associated with adaptive downsizing of the antigravity muscles and the energy deficit. This is seen in other responses, such as fight-or-flight, the presence of a new pathogen or virus, or some sort of injury to the body. Other conditions that affect the pharmacological capabilities of drugs are hypoxia, where drug antagonism is almost negligible in lower blood oxygen levels and physiologic enzyme conditions are limited in high oxygen tension conditions. In addition, diuretics cans shift the oxygen-hemoglobin curve, affecting drug performance.
The U.S. Green Restaurant Association does not allow polystyrene foam to be used as part of its certification standard. Several green leaders, including the Dutch Ministry of the Environment, advise people to reduce their environmental harm by using reusable coffee cups. In March 2019, Maryland banned polystyrene foam food containers and became the first state in the country to pass a food container foam ban through the state legislature. Maine was the first state to officially get a foam food container ban onto the books. In May 2019, Maryland Governor Hogan allowed the foam ban (House Bill 109) to become law without a signature making Maryland the second state to have a food container foam ban on the books, but is the first one to take effect on 1 July 2020. In September 2020, the New Jersey state legislature voted to ban disposable foam food containers and cups made of polystyrene foam.
Sources: en.wikipedia.org
=== Inhalation === Incidental exposure to sulfur dioxide is routine, e.g. the smoke from matches, coal, and sulfur-containing fuels like bunker fuel. Relative to other chemicals, it is only mildly toxic and requires high concentrations to be actively hazardous. However, its ubiquity makes it a major air pollutant with significant impacts on human health. In 2008, the American Conference of Governmental Industrial Hygienists reduced the short-term exposure limit to 0.25 parts per million (ppm). In the US, the OSHA set the PEL at 5 ppm (13 mg/m3) time-weighted average. Also in the US, NIOSH set the IDLH at 100 ppm. In 2010, the EPA "revised the primary SO2 NAAQS by establishing a new one-hour standard at a level of 75 parts per billion (ppb). EPA revoked the two existing primary standards because they would not provide additional public health protection given a one-hour standard at 75 ppb."
=== The principle of conditionality === In the early Buddhist texts, the basic principle of conditionality is called by different names such as "the certainty (or law) of dhamma" (dhammaniyāmatā), "suchness of dharma" (法如; *dharmatathatā), the "enduring principle" (ṭhitā dhātu), "specific conditionality" (idappaccayatā) and "dhammic nature" (法爾; dhammatā). This principle is expressed in its most general form as follows:
== Stigmata and gender == In the late nineteenth century, a French physician named Dr. Antoine Imbert-Goubeyre began compiling a census of known stigmatics from the thirteenth century to his own time. This census includes 280 female and 41 male stigmatics, meaning women comprise a little over 87% of the list. Additionally, the University of Antwerp released a database of information on 244 stigmatics in April 2019. 92% of the stigmatics in the database are female. In some cases, convent sisters have attempted to shield stigmatic women from public scrutiny, often out of fear of how their condition would affect the convent's reputation. So, the number of women stigmatics may be even higher than historical record shows. Despite the high number of women stigmatics throughout history, the best-known and least contested stigmatics, such as Francis of Assisi and Padre Pio, have been men.
Sources: en.wikipedia.org
=== Strategies === A long-acting insulin is used to approximate the basal secretion of insulin by the pancreas, which varies in the course of the day. NPH/isophane, lente, ultralente, glargine, and detemir may be used for this purpose. The advantage of NPH is its low cost, the fact that you can mix it with short-acting forms of insulin, thereby minimizing the number of injections that must be administered, and that the activity of NPH will peak 4–6 hours after administration, allowing a bedtime dose to balance the tendency of glucose to rise with the dawn, along with a smaller morning dose to balance the lower afternoon basal need and possibly an afternoon dose to cover evening need. A disadvantage of bedtime NPH is that if not taken late enough (near midnight) to place its peak shortly before dawn, it has the potential of causing hypoglycemia. One theoretical advantage of glargine and detemir is that they only need to be administered once a day, although in practice many people find that neither lasts a full 24 hours. They can be administered at any time during the day as well, provided that they are given at the same time every day. Another advantage of long-acting insulins is that the basal component of an insulin regimen (providing a minimum level of insulin throughout the day) can be decoupled from the prandial or bolus component (providing mealtime coverage via ultra-short-acting insulins), while regimens using NPH and regular insulin have the disadvantage that any dose adjustment affects both basal and prandial coverage.
The report stated that "continued destruction which came after the ceasefire agreement was not justifiable by any means" and noted that since "extended Russian military action reaching out into Georgia was conducted in violation of international law, Georgian military forces were acting in legitimate self-defence under Article 51 of the UN Charter." Although further Russian military advances into the Georgian territories were explained by the Russian authorities as necessitated to avert possible Georgian counter-attacks from the Gori Municipality and to avert "imminent Georgian attack on Abkhazia", the commission noted that "The Georgian armed forces were hardly ever able to conduct military operations on two fronts at the same time", and "In practical terms, there were no Georgian combat troops in western Georgia when the Russian operation there started". The commission noted, "Georgia did not use force against Russian troops on Russian territory, but only on Georgian territory." The commission stated that an attack by Georgian troops on Russian peacekeepers present in Georgia – "if not in self-defence against a Russian attack", would not be justified. The commission wrote that it was "not entirely clear that Georgian military action against the base was aimed specifically at Russia".
Panthenol is an odourless, slightly bitter, highly viscous, transparent, and colourless liquid at room temperature, but salts of pantothenic acid (for example sodium pantothenate) are powders that are typically white. It is easily soluble in water and alcohol, moderately soluble in diethyl ether, soluble in chloroform (1:100), in propylene glycol, and slightly soluble in glycerin. Panthenol's expanded chemical formula is HO–CH2–C(CH3)2–CH(OH)–CONH–CH2CH2CH2–OH.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.